During the corresponding time, Polomar Health Services, Inc. recorded a revenue increase by 27694.64 % year on year, sequentially revenue grew by 52.03 %. While revenue at the Polomar Health Services, Inc.'s corporate clients
Polomar Health Services's Comment on Sales, Marketing and Customers
Polomar Pharmacy primarily fulfills prescriptions online for GLP-1 agonist and erectile dysfunction medications, having transitioned from a local fulfillment model focused on compounded dermatological formulations. The company provides prescription fulfillment services to third-party web-based telehealth platforms, including contracts with ForHumanity Health, Inc. for inhalable sildenafil and CareValidate for sterile GLP-1 agonist weight loss drugs. Polomar Pharmacy plans to launch SlimRx, an online weight loss platform that connects patients with healthcare providers to prescribe weight loss medications compounded with complementary formulations. The company anticipates growth in its wholesale business segment as it adds customers and expands fulfillment capacity. The market includes competitors such as Hims/Hers and Ro, which hold significant market share in GLP-1 agonist weight loss drugs and erectile dysfunction formulations.
Polomar Health Services’s Comment on Sales, Marketing and Customers
Polomar Pharmacy primarily fulfills prescriptions online for GLP-1 agonist and erectile dysfunction medications, having transitioned from a local fulfillment model focused on compounded dermatological formulations. The company provides prescription fulfillment services to third-party web-based telehealth platforms, including contracts with ForHumanity Health, Inc. for inhalable sildenafil and CareValidate for sterile GLP-1 agonist weight loss drugs. Polomar Pharmacy plans to launch SlimRx, an online weight loss platform that connects patients with healthcare providers to prescribe weight loss medications compounded with complementary formulations. The company anticipates growth in its wholesale business segment as it adds customers and expands fulfillment capacity. The market includes competitors such as Hims/Hers and Ro, which hold significant market share in GLP-1 agonist weight loss drugs and erectile dysfunction formulations.
Sources:
Polomar Health Services, Inc.’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Polomar Health Services, Inc.’s corporate clients.
For your research, we’ve provided 9 tables on Polomar Health Services, Inc. corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
165.73 %